Leukapheresis Market Driven by Rising Blood-Related Disorders, Advanced Technologies, and Growing Demand for Personalized Medicine, the ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Dr. Lubor Gaal joins MitoRx on a part-time basis, bringing over 25 years of global experience in business development, licensing, and strategic partnerships within the pharmaceutical and biotechnology ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

The stock's fall snapped a two-day winning streak.

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.

The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...